[
  {
    "ts": "2025-11-20T12:30:00+00:00",
    "headline": "Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer",
    "summary": "HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Humana, Inc. (NYSE: HUM), effective October 29, 2025, covering approximately 16 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT). This brings CNSide CSF TCE LDT total pol",
    "url": "https://finance.yahoo.com/news/plus-therapeutics-secures-national-coverage-123000391.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c12a3b2c-e09d-330e-aa6e-f8208b1e995e",
      "content": {
        "id": "c12a3b2c-e09d-330e-aa6e-f8208b1e995e",
        "contentType": "STORY",
        "title": "Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer",
        "description": "",
        "summary": "HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Humana, Inc. (NYSE: HUM), effective October 29, 2025, covering approximately 16 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT). This brings CNSide CSF TCE LDT total pol",
        "pubDate": "2025-11-20T12:30:00Z",
        "displayTime": "2025-11-20T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/074aebb13f06b6153b38a42de867fde2",
          "originalWidth": 1566,
          "originalHeight": 896,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MJ9f70ufm3I4X.VW_ofzwg--~B/aD04OTY7dz0xNTY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/074aebb13f06b6153b38a42de867fde2.cf.webp",
              "width": 1566,
              "height": 896,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sSgMXJ76eTj.gy2iYU5_7w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/074aebb13f06b6153b38a42de867fde2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/plus-therapeutics-secures-national-coverage-123000391.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/plus-therapeutics-secures-national-coverage-123000391.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PSTV"
            },
            {
              "symbol": "HUM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]